Mucopolysaccharidosis I

Mucopolysaccharidosis I: Symptoms, Causes, Types, Diagnosis, and Treatments

Mucopolysaccharidosis I (MPS I) is a rare, inherited metabolic disorder that affects the body’s ability to break down glycosaminoglycans (GAGs), formerly known as mucopolysaccharides. GAGs are complex sugars that play vital roles in building connective tissues and supporting cellular function. When the body cannot process these molecules, they accumulate in cells, leading to progressive damage in multiple organs and tissues. Mucopolysaccharidosis I is part of a broader group of conditions known as lysosomal storage disorders.

This article explores Mucopolysaccharidosis I in detail, focusing on its symptoms, causes, types, diagnosis, and treatment options. Whether you are a caregiver, healthcare professional, or simply seeking to understand this condition better, this comprehensive guide aims to provide clarity and insight into MPS I.

---

What is Mucopolysaccharidosis I?

Mucopolysaccharidosis I is caused by a deficiency of an enzyme called alpha-L-iduronidase. This enzyme is responsible for breaking down two specific types of glycosaminoglycans: dermatan sulfate and heparan sulfate. Without enough of this enzyme, these substances build up inside cells, leading to damage over time.

Mucopolysaccharidosis I is an autosomal recessive genetic disorder, meaning both parents must pass on the faulty gene for a child to be affected. The disorder is categorized into three subtypes based on the severity of symptoms: Hurler syndrome (severe), Hurler-Scheie syndrome (moderate), and Scheie syndrome (mild). These classifications are now often referred to as MPS I H, MPS I H/S, and MPS I S, respectively.

---

Symptoms of MPS I

The symptoms of Mucopolysaccharidosis I can vary widely depending on the severity of the condition. In general, the symptoms tend to appear during infancy or early childhood and become progressively worse over time.

Common Symptoms

• Coarse facial features: A flat nasal bridge, thick lips, enlarged tongue, and prominent forehead
• Enlarged liver and spleen (hepatosplenomegaly)
• Joint stiffness or restricted movement
• Short stature and abnormal skeletal development (dysostosis multiplex)
• Corneal clouding, leading to visual impairment
• Chronic ear infections and hearing loss
• Delayed cognitive development or intellectual disability
• Sleep apnea and frequent upper respiratory infections
• Cardiac problems, including valve dysfunction
• Hernias (umbilical or inguinal)

Progressive Symptoms

Over time, individuals may experience:

• Spinal cord compression
• Severe joint deformities
• Loss of motor functions
• Worsening respiratory issues
• Increased intracranial pressure (hydrocephalus)

The severity and progression of these symptoms vary among the three types of MPS I.

---

Types of MPS I

Traditionally, Mucopolysaccharidosis I is categorized into three subtypes. Though they represent a spectrum rather than clearly defined categories, each has distinctive clinical features.

1. Hurler Syndrome (MPS I H)

• Onset: Within the first two years of life
• Severity: Most severe form
• Symptoms:
  • Profound developmental delay
  • Severe skeletal abnormalities
  • Corneal clouding
  • Enlarged organs
  • Heart valve disease
• Prognosis: Without treatment, children typically do not live beyond the first decade of life.

2. Hurler-Scheie Syndrome (MPS I H/S)

• Onset: Between ages 3 to 6
• Severity: Intermediate
• Symptoms:
  • Milder cognitive impairment
  • Joint stiffness
  • Some cardiac involvement
  • Moderate skeletal changes
• Prognosis: Survival into teenage years or adulthood with appropriate treatment

3. Scheie Syndrome (MPS I S)

• Onset: Childhood to early adolescence
• Severity: Mildest form
• Symptoms:
  • Normal intelligence
  • Joint stiffness
  • Corneal clouding
  • Mild skeletal changes
• Prognosis: Many individuals live into adulthood with varying degrees of physical disability

---

Causes of MPS I

Mucopolysaccharidosis I is caused by mutations in the IDUA gene (located on chromosome 4), which encodes the enzyme alpha-L-iduronidase. More than 100 mutations in the IDUA gene have been identified, and the type of mutation can influence the severity of the disease.

Genetic Inheritance

MPS I is inherited in an autosomal recessive pattern, which means:

• A child must inherit two copies of the mutated gene—one from each parent—to develop the disease.
• Parents who carry one mutated copy are called carriers and usually do not show symptoms.
• When two carriers have a child, there is a:
  • 25% chance the child will be affected
  • 50% chance the child will be a carrier
  • 25% chance the child will have two normal genes

---

Diagnosis of MPS I

Early diagnosis is crucial for effective management of MPS I. Prompt intervention can slow disease progression and improve quality of life.

1. Clinical Evaluation

Initial signs that may lead to suspicion of Mucopolysaccharidosis I include:

• Developmental delay
• Recurrent infections
• Unusual facial features
• Organ enlargement

Pediatricians may refer the child to a geneticist or metabolic specialist based on these signs.

2. Urine Tests

• Urinalysis may show elevated levels of glycosaminoglycans (GAGs), especially dermatan sulfate and heparan sulfate.
• While this test is non-invasive, it is not definitive and needs to be confirmed with enzyme assays.

3. Enzyme Activity Test

• The gold standard diagnostic test for MPS I.
• Measures the activity of alpha-L-iduronidase in blood, fibroblasts, or leukocytes.
• Reduced or absent enzyme activity confirms the diagnosis.

4. Genetic Testing

• Identifies mutations in the IDUA gene.
• Useful for confirming the subtype and for prenatal diagnosis in future pregnancies.

5. Newborn Screening

• In some regions, MPS I is included in the newborn screening panel.
• Early identification through dried blood spot testing can lead to timely treatment.

---

Treatments for MPS I

There is no cure for Mucopolysaccharidosis I , but several treatment options can significantly reduce symptoms and improve life expectancy. Management is multidisciplinary, often involving specialists in genetics, cardiology, orthopedics, ophthalmology, and neurology.

1. Enzyme Replacement Therapy (ERT)

• Laronidase (Aldurazyme®) is a synthetic version of the alpha-L-iduronidase enzyme.
• Administered via intravenous infusion, typically once a week.
• Benefits:
  • Reduces liver and spleen size
  • Improves respiratory function
  • Enhances mobility
  • Reduces joint stiffness
• Limitations:
  • Does not cross the blood-brain barrier, so cognitive decline may continue in severe forms.

2. Hematopoietic Stem Cell Transplantation (HSCT)

• Especially effective in Hurler syndrome if performed before age 2.
• Donor stem cells produce the missing enzyme throughout the body, including the brain.
• Benefits:
  • Can halt or slow neurological decline
  • Long-term improvement in systemic symptoms
• Risks:
  • Graft-versus-host disease
  • Transplant-related complications

3. Gene Therapy (Investigational)

• Promising emerging treatment
• Introduces a functional copy of the IDUA gene into the patient’s cells.
• Currently in clinical trials, with the potential to provide a one-time, long-lasting treatment.

4. Supportive and Symptomatic Treatments

a. Orthopedic Management

• Surgery for joint contractures, scoliosis, or hip dysplasia
• Physical therapy to maintain mobility

b. Cardiac Care

• Regular monitoring of heart function
• Valve replacement surgery if needed

c. Ophthalmologic Care

• Corneal transplantation for severe clouding
• Regular eye exams to monitor vision

d. Audiologic Management

• Hearing aids or cochlear implants
• Surgery for chronic ear infections

e. Pulmonary Support

• CPAP or BiPAP for sleep apnea
• Surgical intervention for airway obstructions

---

Living with MPS I

MPS I affects nearly every system in the body, so managing daily life can be challenging for patients and caregivers. However, with early intervention and a comprehensive care plan, many individuals live fulfilling lives.

Psychological and Social Support

• Emotional counseling for patients and families
• Special education services for cognitive challenges
• Support groups and advocacy organizations

Nutritional Support

• Balanced diet to support growth and development
• Nutritional supplements as needed

Regular Monitoring

• Routine evaluations by a multidisciplinary team
• Early detection of complications can greatly improve outcomes

---

Prognosis

The prognosis of Mucopolysaccharidosis I largely depends on the age at diagnosis, type of MPS I, and the availability of treatment. Children with Hurler syndrome typically face a reduced life expectancy without intervention, while those with Scheie syndrome may live into adulthood with manageable symptoms.

Early treatment, particularly with ERT and HSCT, can dramatically alter the disease course. Ongoing research and newer therapies, such as gene editing and next-generation enzyme replacement, are offering hope for improved outcomes in the future.

---

Conclusion

Mucopolysaccharidosis I is a complex and life-altering condition. Caused by a deficiency in the alpha-L-iduronidase enzyme, it leads to the accumulation of harmful substances in the body, resulting in a wide range of physical and cognitive symptoms. However, thanks to advancements in medical science—including enzyme replacement therapy and stem cell transplantation—many individuals affected by MPS I can lead longer and healthier lives.

Key takeaways:

• Mucopolysaccharidosis I is a genetic lysosomal storage disorder with a spectrum of severity.
• Early diagnosis and intervention are critical for improving outcomes.
• Treatments like ERT and HSCT can significantly reduce symptoms and improve quality of life.
• Ongoing support from healthcare providers, families, and communities is essential.

Raising awareness about MPS I is crucial for improving early detection and expanding access to life-saving treatments. If you or someone you know may be affected, seek consultation with a genetic specialist for proper evaluation and support.

Frequently Asked Questions (FAQs) About Mucopolysaccharidosis I

For more details keep visiting our Website & Facebook Page.